Surface Logix has used its Pharmacomer™ Technology Platform to rapidly identify small molecule drugs against enteric targets resulting in improved enteric efficacy with reduced systemic liability. This approach is specifically applicable to many metabolic disease targets and has allowed the company to identify novel enteric inhibitors of caloric absorption as well as novel enteric effectors of appetite suppression which along with SLx’s systemic but non-CNS penetrating selective ROCK metabolism program address all three thermodynamic mechanisms to treat obesity